

AstraZeneca, Medical Education Grants Office (MEGO) Request for Proposal (RFP) for an Independent Medical Education Grant

Topic:	Trophoblast Cell Surface Antigen 2 (TROP2) expressing Non-Small Cell Lung Cancer (NSCLC)
Therapeutic Focus:	Thoracic Immuno-Oncology (IO)
Recommended Learning Format:	Can include but not limited to: Live virtual/online, multidisciplinary, faculty-led panels utilizing a case-based learning approach, patient simulation, online enduring component, downloadable resources (handouts, slides), podcast, and/or social media components.
Target Audience:	Academic and community Learners include thoracic oncologists, thoracic surgeons, medical oncologists, pathology specialists, molecular pathology, pulmonologists, pharmacists, NP's, PA's, allied health, and other lung cancer professionals involved in the care of patients with NSCLC
Application Due Date:	October 1, 2026, for initial review
Final Grant Decision:	Grant decisions will be made on a rolling basis through 2027, budget permitting
Estimated Program Start Date:	November 2026
Submission Information and Inquiries:	grants@astrazeneca.com www.astrazenecagrants.com Ray Facciolo, Associate Director, Medical Education and Grants Office, ray.facciolo@astrazeneca.com

Strategic Imperatives and Request:

We are accepting grant proposals for independent medical education that reinforce multidisciplinary team (MDT) best practice coordination in diagnosis, treatment decisions and management of TROP2 expressing Non-Small Cell Lung Cancer (NSCLC).

Proposals may address topics incorporating guidelines and appropriate treatment options, recent clinical trial data, and outcomes, including:

- Advancing quantitative biomarker literacy in NSCLC
- Building competency in computational pathology and AI-assisted diagnostics
- Optimizing multidisciplinary test-to-treat decision-making
- Improving integration of emerging biomarkers into evidence-based care
- Preparing healthcare professionals for the future diagnostic landscape in lung cancer

We welcome submissions for independent medical education grants from educational providers who believe they can meet the high demands of time-sensitive rapid grant submission and deployment of virtual medical education. Submitted applications should include a formal letter of request and grant proposal with needs assessment, learning objectives, agenda, and budget schedule.

AstraZeneca, Medical Education Grants Office (MEGO):

AstraZeneca is committed to supporting quality independent medical education that meets an educational need by providing information to healthcare professionals to improve patient care and outcomes. We support education that furthers the understanding of emerging therapies based on a documented unmet need and support the efforts of health care professionals to broaden patient knowledge and awareness of disease states and treatment options. Our grant support is focused on areas of high unmet need that overlap with our medical areas of interest. For more information, please visit www.astrazenecagrants.com